Sodium Hydroxide → (5-{2-[4-(2-Bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid
Reaktionsgleichung
[Br:1][C:2]1[CH:29]=[CH:28][C:27]([F:30])=[CH:26][C:3]=1[O:4][CH:5]1[CH2:10][CH2:9][N:8]([C:11]2[N:16]=[CH:15][C:14]([C:17]3[N:18]=[N:19][N:20]([CH2:22][C:23]([O-:25])=[O:24])[N:21]=3)=[CH:13][N:12]=2)[CH2:7][CH2:6]1.[OH-].[Na+]>>[Br:1][C:2]1[CH:29]=[CH:28][C:27]([F:30])=[CH:26][C:3]=1[O:4][CH:5]1[CH2:10][CH2:9][N:8]([C:11]2[N:12]=[CH:13][C:14]([C:17]3[N:18]=[N:19][N:20]([CH2:22][C:23]([OH:25])=[O:24])[N:21]=3)=[CH:15][N:16]=2)[CH2:7][CH2:6]1Komponenten
3
Versuchsvorschrift
The title compound was prepared in a similar manner as that described for Example 3 (step 5) from ethyl ((5-{2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetate and aqueous NaOH.
Quellen und Nachweise
- ORD-Eintrag
- ord-2943fe2384b94b7d8d29356aedcb9649
- Quelldatensatz
- uspto-grants-2009_09